cholestanol has been researched along with Nervous System Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brilstra, EH; Haak, HR; Hollak, CEM; Huidekoper, HH; Kluijtmans, LAJ; Stelten, BML; van de Warrenburg, BPC; Verrips, A; Wevers, RA | 1 |
| Moghadasian, MH | 1 |
1 review(s) available for cholestanol and Nervous System Disorders
| Article | Year |
|---|---|
Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds.
Topics: Bile Acids and Salts; Cataract; Cholestanetriol 26-Monooxygenase; Cholestanol; Cholesterol; Codon; Databases as Topic; Diagnosis, Differential; Genotype; Humans; Liver; MEDLINE; Mutation; Nervous System Diseases; Steroid Hydroxylases; Xanthomatosis, Cerebrotendinous | 2004 |
1 other study(ies) available for cholestanol and Nervous System Disorders
| Article | Year |
|---|---|
Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Cholestanetriol 26-Monooxygenase; Cholestanol; Cohort Studies; Disability Evaluation; Disease Management; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Mutation; Nervous System Diseases; Time Factors; Treatment Outcome; Xanthomatosis, Cerebrotendinous; Young Adult | 2019 |